The company’s first-quarter update emphasizes strong phase 2 results for daridorexant in children, ongoing real-world studies in patients with co-morbidities, and advancements in its sleep medicine pipeline.
Key takeaways:
- Idorsia reported outstanding phase 2 results for pediatric daridorexant, demonstrating clinically meaningful improvements across multiple sleep measures in children with insomnia disorder.
- The company is generating additional clinical evidence for QUVIVIQ in patients with co-morbidities, including depression, anxiety, and Alzheimer’s disease, and is consulting with the FDA on a daytime functioning label-enabling study.
- Focused drug discovery efforts are advancing on prioritized breakthrough projects, including a potential best-in-class orexin receptor agonist for narcolepsy and other central nervous system disorders.
Idorsia Ltd announced its financial results for the first quarter of 2026, highlighting significant advancements in its sleep medicine portfolio, including positive pediatric data for daridorexant and expanding clinical evidence for QUVIVIQ across various patient populations.
“We have made a strong start to 2026. QUVIVIQ sales are tracking in line with our expectations, our pipeline is advancing, and we have delivered excellent results with daridorexant in children,” says Jean-Paul Clozel, chairman and interim CEO of Idorsia, in a release. “Our focus is now firmly on executing the actions that will accelerate growth and unlock Idorsia’s full value. Building on the solid foundation established by our commercial team, we are working to further change the sales trajectory and accelerate growth, generating the cash flow required to continue advancing our breakthrough portfolio.”
Daridorexant in Pediatrics
- Outstanding phase 2 results in children: statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children with insomnia disorder, with especially pronounced efficacy in those with comorbid neurodevelopmental disorders.
- Excellent safety and tolerability, confirmed for the first time in a pediatric population, including at the adult-recommended 50 mg dose.
- Full analysis is ongoing with scientific publications and discussions with health authorities in preparation.
QUVIVIQ (daridorexant) and Clinical Evidence
- QUVIVIQ continues to reshape the insomnia treatment landscape, and Idorsia is investing to accelerate its trajectory toward blockbuster status.
- Net sales increased 74% to CHF 44 million in Q1 2026 (Q1 2025: CHF 25 million) across North America and Europe.
- QUVIVIQ is now available in 13 countries across Europe, North America, China, and Japan, reflecting the continued global expansion of the franchise. Further market introductions are planned in Benelux, Ireland, Norway, Denmark, and Central and Eastern Europe, complemented by new strategic commercial alliances, most recently in Latin America, United Arab Emirates, Kuwait, Qatar, Oman, and Bahrain, to extend geographic reach and scale.
- QUVIVIQ has secured public reimbursement in key European markets, including France, Germany, the United Kingdom, and Austria. Efforts to further expand reimbursed access are ongoing, with active discussions in Spain—the largest insomnia market in Europe—and in the Nordics. In the US, QUVIVIQ benefits from broad insurance coverage, although the current scheduled status continues to limit prescribing; the descheduling process for the DORA class remains ongoing.
- In Europe and Canada, Idorsia promotes QUVIVIQ to specialist prescribers, supported by co-promotion partnerships extending to primary care. Following partnerships in France in 2024 and Germany in 2025, co-promotions in the United Kingdom and Switzerland were launched in the first quarter of 2026. Additional co-promotion agreements are planned to further expand reach into primary care.
- Further sales acceleration is expected to be driven by increased private market awareness, including a strengthened presence in rapidly growing online prescription channels, alongside scalable direct-to-patient and adherence-focused initiatives designed to improve patient access.
- In parallel, Idorsia’s medical teams continue to generate additional clinical evidence, with ongoing studies in real-world settings and in patients with co-morbidities, including depression and anxiety, COMISA, major depressive disorder, alcohol and opioid use disorder, smoking cessation, and Alzheimer’s disease, reinforcing QUVIVIQ’s differentiated profile across a broad range of patient populations.
Sleep Research & Development
- Daridorexant daytime functioning (IDSIQ) label-enabling study in consultation with the US FDA.
- Focused drug discovery efforts advancing on prioritized breakthrough projects such as Idorsia’s potential best-in-class orexin receptor agonist for narcolepsy and other orexin-related central nervous system disorders.
Financial Highlights and Guidance
The company reported the following financial highlights for Q1 2026:
- QUVIVIQ sales: CHF 44 million (excluding sales to partners)
- Contract revenues (one-off): CHF 11 million
- Non-GAAP operating expenses: CHF 78 million
- Non-GAAP operating loss: CHF 24 million (US GAAP: CHF 26 million)
Financial guidance for 2026 remains unchanged:
- QUVIVIQ sales: CHF 200 million
- Non-GAAP operating expenses: ~CHF 330 million
- Non-GAAP operating loss: ~CHF 120 million (US GAAP operating loss: ~CHF 160 million)
